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The myocardial extracellular matrix (ECM), an in-
terwoven meshwork of proteins, glycoproteins,
proteoglycans, and glycosaminoglycans that is
dominated by polymeric fibrils of type I collagen,
serves as the mechanical scaffold on which myo-
cytes are arrayed for coordinated and synergistic
force transduction. Following ischemic injury, car-
diac ECM remodeling is initiated via localized pro-
teolysis, the bulk of which has been assigned to
matrix metalloproteinase (MMP) family members.
Nevertheless, the key effector(s) of myocardial type
I collagenolysis both in vitro and in vivo have re-
mained unidentified. In this study, using cardiac
explants from mice deficient in each of the major
type I collagenolytic MMPs, including MMP-13,
MMP-8, MMP-2, MMP-9, or MT1-MMP, we identify the
membrane-anchored MMP, MT1-MMP, as the domi-
nant collagenase that is operative within myocar-
dial tissues in vitro. Extending these observations
to an in vivo setting, mice heterozygous for an MT1-
MMP–null allele display a distinct survival advan-
tage and retain myocardial function relative to wild-
type littermates in an experimental model of
myocardial infarction, effects associated with pres-
ervation of the myocardial type I collagen network
as a consequence of the decreased collagenolytic
potential of cardiac fibroblasts. This study identifies
MT1-MMP as a key MMP responsible for effecting
postinfarction cardiac ECM remodeling and cardiac
dysfunction. (Am J Pathol 2012, 180:1863–1878; DOI:
10.1016/j.ajpath.2012.01.022)The cardiac extracellular matrix (ECM) is an interwoven
meshwork of proteins, glycoproteins, proteoglycans, and
glycosaminoglycans that provide the structural scaffold
on which myocytes, cardiac fibroblasts, and endothelial
cells are arrayed to form functional heart tissue.1–4 Dom-
inated by fibrils of triple helical type I collagen, the car-
diac ECM serves to maintain myocyte geometrical integ-
rity for synergistic force transduction while also serving
as a reservoir of latent bioactive signaling molecules that
regulate cardiac function.1–4 In the setting of myocardial
infarction (MI), ischemic tissue injury generates profound
changes in the architecture and composition of the car-
diac ECM: hypoxic cell death of myocytes and oxidative
damage following reperfusion induces an influx of inflam-
matory leukocytes that collaborate with stromal cells to
degrade the native structural components of the ventric-
ular wall, resulting in ventricular thinning and dilation.5–10
Following clearance of necrotic tissue, neomatrix is
deposited, with the wound resolving as an inelastic
scar.6,7,11 Loss of functional cardiac tissue manifests ei-
ther acutely, if uncompensated, as cardiogenic shock or
chronically as congestive heart failure, resulting in signif-
icant morbidity and mortality.2,5–8,12 As such, recent
studies have focused on identifying the key effectors of
post-MI cardiac ECM remodeling in an effort to develop
therapeutic interventions that might better preserve tis-
sue architecture and function.11,13–15
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AJP May 2012, Vol. 180, No. 5The matrix metalloproteinases (MMPs), a family of
more than 20 zinc-dependent endopeptidases that col-
lectively can degrade all ECM macromolecules, are mo-
lecular effectors of post-MI tissue remodeling, likely via
the catabolism of type I collagen within the cardiac inter-
stitium.12,15,16 Consistent with this hypothesis, multiple
studies have demonstrated increased MMP expression
and activation in the post-MI state.15,17–20 Further, a func-
tional role for MMPs in post-MI cardiac remodeling is
supported by studies wherein MMP inhibition preserves
cardiac function in animal models.13,15,21–24 Comple-
menting these studies, genetically engineered mice car-
rying disrupted genes encoding a subset of MMPs or
endogenous MMP inhibitors display significant altera-
tions in post-MI cardiac remodeling or survival.25–34 Al-
though these studies support a model wherein excessive
MMP-mediated cardiac ECM remodeling contributes ad-
versely to post-MI systolic dysfunction, the key MMPs
responsible for type I collagenolysis in the infarcted heart
remain controversial.
Until recently, the dissolution of type I collagen-rich
networks in murine tissues has largely been attributed to
the secreted type I collagenolytic MMPs, MMP-13,
MMP-8, MMP-2, or MMP-9.16,35 However, membrane
type-1 MMP (MT1-MMP) is a cell-surfaced anchored
MMP that also functions as a highly effective, pericellular
type I collagenase.35–38 Studies using mice deficient for
this MMP have identified required roles for the enzyme in
diverse developmental settings,39–42 but the role played
by MT1-MMP within the ischemic myocardium remains
largely unexplored. Herein, using explanted myocardial
tissues isolated from MMP-13/, MMP-8/, MMP-2/,
MMP-9/, or MT1-MMP/ mice, we demonstrate that
MT1-MMP is the major type I collagenase operative within
the ischemic myocardium. Furthermore, mice heterozy-
gous for a null allele of MT1-MMP display functional ad-
vantages post-MI due to preserved cardiac function that
occurs in tandem with the attenuated remodeling of the
cardiac ECM. These results identify MT1-MMP as a key
effector of the post-MI ECM remodeling that accompa-
nies cardiac dysfunction.
Materials and Methods
Mice
All ex vivo and in vivo studies were performed with MMP2/
C57BL/6 mice,43 MMP8/ C57BL/6/129 mice,44 MMP9/
129SvEv mice,45 MMP13/ C57BL/6 mice,46 or MT1-
MMP/ or MT1-MMP/ Swiss Black mice,39 all back-
crossed 6 generations. Age-matched C57BL/6 animals
were used as controls forMMP-2/,MMP-8/, andMMP-
13/ mice, and 129SvEv animals were used as controls for
MMP-9/ mice. For studies of MT1-MMP/ or MT1-
MMP/mice, paired analyseswere performedwithwild-type
(WT) littermates.
Tissue Explants and Cell Isolation
Whole-heart tissue explants were isolated from mice per-
fused with saline, minced into 1-mm3 fragments, andplaced in 10-mL centrifuge tubes with Dulbecco’s mod-
ified Eagle’s medium (Gibco BRL, Carlsbad, CA) supple-
mented with 10% fetal bovine serum and incubated un-
der 5% CO2 at 37°C.
47 In selected experiments, tissue
samples were cultured in the presence of the synthetic
MMP inhibitors 5 mol/L BB-94 (Tocris, Minneapolis, MN)
or 25 mol/L GM6001 (Calbiochem, Merck, Darmstadt,
Germany). After 3 and 5 days in culture, supernatant
and heart tissue samples were collected for analysis.
Collagen degradation products were quantified by hy-
droxyproline release into the conditioned medium after
an ethanol precipitation step (70% v/v) as de-
scribed.37,48 Sirius Red staining was performed as de-
scribed,49 whereas denatured type I collagen degra-
dation products were detected in situ with a
monoclonal antibody directed against hydrolyzed type
I collagen.40,50
Cardiac fibroblasts were isolated from the left ventricle
of 10- to 12-week-old MT1-MMP/, MT1-MMP/, or
MT1-MMP/mice (passage 2 to 4) and were cultured in
Dulbecco’s modified Eagle’s medium supplemented with
10% heat-inactivated fetal calf serum (Atlanta Biologi-
cals, Lawrenceville, GA), 100 units/mL penicillin, 100
g/mL streptomycin, 0.25 g/mL Fungizone, and 2
mmol/L L-glutamine (Gibco).
Animal Models
Female mice, ranging in age from 10 weeks to 12 weeks,
and in weight from 20 g to 30 g, underwent coronary
artery ligation for the induction of MI. Surgical procedures
have been described in detail elsewhere.51 Briefly, mice
were sedated with intraperitoneal sodium pentobarbital
(45 mg/kg), intubated orally, and ventilated via a pres-
sure-controlled ventilator (Harvard Apparatus, Holliston,
MA) with 1% isoflurane in 100% oxygen at a peak inspira-
tory pressure of 15 cm H2O and a respiratory rate of 60
breaths per minute. With the aid of a dissecting micro-
scope, the heart was exposed via a left thoracotomy, and
the proximal portion of the left coronary artery was ligated
1 to 2 mm from the left atrium with a 7-0 silk suture. Pallor,
regional hypokinesia, and enlargement of the left ventri-
cle confirmed the presence of an infarction. The chest
was filled with warm sterile saline to evacuate air, and the
incision was closed in layers using 5-0 silk suture. The
animals were then extubated and allowed to recover from
surgery under a heating lamp for 1 hour. Antibiotic pro-
phylaxis was not given, but no apparent infection devel-
oped in any animal during the course of the study or at
the time of autopsy. Bone marrow transplantation of 8- to
10-week-old MT1-MMP/ mice with MT1-MMP/ or
MT1-MMP/ marrow was performed as described.52
Animals were maintained under standard housing condi-
tions following experimental MI with careful monitoring for
health status. Animals were euthanized at 3, 14, or 28
days post-MI for analysis of cardiac disease as de-
scribed below. Post-MI mortality was monitored through-
out this period. All animal protocols were approved by the
University of Michigan Committee on Use and Care of
Animals. Mice were housed in the American Association
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facility of the University of Michigan.
Echocardiography
Echocardiographic studies were performed under light
anesthesia with spontaneous respiration using inhaled
isoflurane, l-chloro-2,2,2-trifluoroethyl difluoromethyl ether
(Avertin; Sigma-Aldrich, St. Louis, MO). An ultrasonogra-
pher experienced in rodent imaging performed the echo-
cardiographic studies, using commercially available
equipment (Sonos Model 5500; Hewlett-Packard Medical
Products Group, Andover, MA) and a 15- to 60-MHz
transducer (Hewlett-Packard). The heart was imaged
with two-dimensional–guided M-mode echocardiogra-
phy in the parasternal long-axis view. From this view, an
M-mode cursor was positioned perpendicular to the in-
terventricular septum and posterior wall of the left ven-
tricle at the level of the papillary muscles, and a sweep
speed of 100 mm/s was used. Diastolic and systolic left
ventricular (LV) wall thickness and left ventricular end-
diastolic and end-systolic chamber dimensions were
measured. Doppler was used for analysis of mitral
valve inflow patterns [early (E) and late (A) filling
waves]. Doppler tissue imaging was used to measure
the early (Ea) and late (Aa) diastolic tissue velocities of
the mitral annulus in the apical four-chamber view. For
each measurement, three consecutive cardiac cycles
were measured and averaged. All measurements were
done from leading edge to leading edge according to
the American Society of Echocardiography guidelines.
Histopathology
After in vivo echocardiographic and hemodynamic stud-
ies, the hearts were excised and dissected. From the
mid-left ventricle transverse sections, 5-m sections
were cut and stained with hematoxylin and eosin for
determination of myocyte cross-sectional area.
Myocardial leukocyte infiltration was quantified in he-
matoxylin-and-eosin–stained sections by determination
of nuclear density (nuclei/mm2). In each animal, five in-
dependent high-power fields were analyzed. To further
determine the number of polymorphonuclear leukocytes
and macrophages, immunohistochemical analysis using
specific antibodies against mouse CD45 and F4/80 (BD
Biosciences PharMingen, San Jose, CA), respectively,
was performed.
Myocardium collagen volume fraction was determined
by quantitative morphometry of Sirius Red–stained sec-
tions (Sigma, St. Louis, MO)49 on a subset of six mice
(three MT1-MMP/ mice and three MT1-MMP/ mice)
with infarcts. The relative abundance of thin (immature)
versus thick (mature) interstitial collagen fibers was esti-
mated by spectral analysis of collagen fiber color emis-
sion (green/yellow versus red/orange, respectively) un-
der polarized microscopy as described previously.53–56
Tissue collagen content and collagen degradation frag-
ments were determined as described above for cardiac
explants. Apoptosis was assessed by TUNEL assay ac-cording to the manufacturer’s protocol (Roche, Basel,
Switzerland).57
Fluorescent and light microscopy images were cap-
tured by a microscope (DMLB; Leica Microsystems,
Wetzlar, Germany) equipped with a SPOT RT camera
(Spot Imaging Solutions, Diagnostic Instruments, Ster-
ling Heights, MI) after calibration using an objective
micrometer.
In Situ Hybridization
Probes specific for mouse MT1-MMP or murine Col1a1
(for type I collagen) were developed as previously de-
scribed.17 After vector linearization, sense and antisense
digoxigenin (Dig)-labeled probes were generated using
the Dig RNA labeling mix (Roche) and SP6 or T7 RNA
polymerase, respectively. Five-micrometer sections were
deparaffinized, rehydrated, and treated with proteinase K
(5 g/mL) for 10 minutes at room temperature and then
fixed in paraformaldehyde. Slides were incubated in
acetylation solution [triethanolamine (pH 8), HCl, acetic
anhydride] for 10 minutes to reduce nonspecific, charge-
based hybridization. Hybridization with 20 ng of probe
was performed overnight at 65°C in a humidity chamber.
Slides were then sequentially washed with 5 standard
saline citrate at room temperature for 5 minutes, 1
standard saline citrate/50% formamide at 60°C for 30
minutes, and TNE [10 mmol/L Tris (pH 7.5), 500 mmol/L
NaCl, 1 mmol/L EDTA (pH 8)] for 10 minutes at 37°C.
Sections were treated with RNase A (20 g/mL in TNE)
for 10 minutes and then washed again in 2 standard
saline citrate followed by 0.2 standard saline citrate
at 60°C. Dig detection was performed with the anti-
Dig-AP antibody (Roche) and developed with the BM
purple substrate (Roche) for 5 days with one change of
the substrate solution as per manufacturer’s direc-
tions.58
RT-PCR Analysis
RNA was isolated from the mouse heart tissue using
TRIzol reagent (Life Technologies, Grand Island, NY).
RT-PCR amplification using specific oligonucleotide
primers for MMP-2, MMP-8, MMP-9, MMP-13, and MT1-
MMP was performed as described.37 The identities of the
PCR products were confirmed by sequence analysis.
Tissue Zymography
Myocardial MMP-2 and MMP-9 activity were determined
in the left ventricle from 12 week-old mice at baseline and
postinfarction by gelatin zymography.31,37,59 The left ven-
tricular myocardial samples were homogenized (30-
second bursts) in 1 mL of an ice-cold extraction buffer
containing cacodylic acid (10 mmol/L), NaCl (0.15 mol/
L), ZnCl2 (20 mmol/L), NaN3 (1.5 mmol/L), and 0.01%
Triton X-100 (pH 5.0). The homogenate was then centri-
fuged (4°C, 10 minutes, 10,000 g), and the supernatant
was decanted and saved on ice. The pH levels of the
samples were adjusted to 7.5 with Tris (1 mol/L). The final
protein concentration of the myocardial extracts was de-
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myocardial extracts were then loaded onto electropho-
retic gels (SDS-PAGE) containing 1 mg/mL gelatin under
nonreducing conditions. Five micrograms of protein was
loaded onto the gels using a 3:1 sample buffer [10%
SDS, 4% sucrose, 0.25 mol/L Tris Cl, and 0.1% bro-
mophenol blue (pH 6.8)]. The gels were run at 15 mA
through the stacking phase (4%) and at 20 mA for the
separating phase (10%), whereas the running buffer tem-
perature was maintained at 4°C. After SDS-PAGE, the
gels were washed twice in 2.5% Triton X-100 for 30 min-
utes each, rinsed in water, and then incubated for 24
hours in a substrate buffer at 37°C [50 mmol/L Tris HCl, 5
mmol/L, CaCl2, and 0.02% NaN3 (pH 7.5)]. After incuba-
tion, the gels were stained with Coomassie Brilliant Blue
R-250.
Subjacent Collagen Degradation Assays
Type I collagen gel films (100 g/cm2) were labeled
with tetramethylrhodamine isocyanate (TRITC; Molec-
ular Probes, Carlsbad, CA)37 and isolated cardiac fi-
broblasts (5  104) were cultured atop the collagen
films for 7 days in Dulbecco’s modified Eagle’s medi-
um/10% fetal bovine serum and PDGF-BB (10 ng/ml) at
37°C. The samples were fixed, polymerized actin was
visualized with Alexa Fluor-488 phalloidin (Molecular
Probes), and fluorescent images were captured by a
laser scanning confocal microscope equipped with ac-
quisition software (Service Pack 2) to visualize the for-
mation of degradative zones.37
Alternatively, type I collagen degradation was visual-
ized by a collagen film assay wherein 24-well plates were
coated with collagen gel (100 g/well) and 5  104
fibroblasts in 35 L of medium were seeded in the center
of each well and allowed to adhere for 8 hours.35,60 After
washing, 0.5 mL of serum-free medium was added to
each well with PDGF-BB (10 ng/mL). After 5 days, cells
were removed by trypsin/EDTA or detergent lysis, and
the remaining collagen film was stained with Coomassie
Brilliant Blue.
Statistical Analysis
All data are expressed as mean  SEM. A survival anal-
ysis was performed by the Kaplan-Meier method, and
between-group difference in survival was tested by the
log-rank test. Between-group comparisons of the means
were performed by one-way analysis of variance followed
by paired Student’s t-test.
Results
MT1-MMP Is Required for Interstitial Collagen
Degradation in Ischemic Myocardial Explants
To assess the collagenolytic potential of myocardium-
derived MMPs ex vivo, explants of WT adult mouse hearts
were cultured under no-flow conditions designed to sim-
ulate an ischemic environment.47 Over the course ofthe 5-day culture period, the collagen volume fraction
decreased as assessed by i) Sirius Red staining; ii) the
accumulation of degraded type I collagen as moni-
tored by the immunohistochemical detection of hydro-
lyzed collagen fragments in the explant tissue; and iii)
the release of small Mr, hydroxyproline-containing pep-
tides into the extracellular media (Figure 1, A and B).
To determine the role of MMPs in the collagenolytic
activity detected under these conditions, explants
were cultured in the presence of the broad-spectrum
MMP inhibitors, BB-94 or GM6001.37 Either agent pre-
served the collagen network of the myocardial intersti-
tium, attenuated the appearance of type I collagen
cleavage products within the interstitium, and inhibited
the appearance of soluble collagen degradation prod-
ucts (Figure 1, A and B).
To define the relative roles of individual MMPs in myo-
cardial collagenolysis, the induction of transcripts encod-
ing each of the known murine type I collagenases (ie,
MMP-13, MMP-8, MMP-2, MMP-9, andMT1-MMP37) was
examined in myocardial explants over a 5-day period.
mRNAs encoding MMP-13, MMP-9, and MT1-MMP were
induced over the 5-day culture period, whereas MMP-2
levels remained stable (Figure 1C). MMP-8 could not be
detected under these conditions (Figure 1C). To identify
the MMP(s) participating in collagenolysis, myocardial
explants were isolated from mice with targeted disruption
of the genes encoding MMP-2, MMP-8, MMP-9, MMP-13,
or MT1-MMP and cultured under no-flow conditions for 5
days. The total collagen content of the explants har-
vested from WT or each of the MMP-deficient mice was
identical at baseline as assessed by hydroxyproline anal-
ysis (data not shown). Although deficiency of any of the
four secreted collagenases (ie, MMP-13, MMP-8, MMP-2,
or MMP-9) failed to significantly blunt ischemia-induced
collagenolysis, the collagenolytic activity of MT1-
MMP/ cardiac explants was attenuated to levels com-
parable to those observed when WT tissues were cul-
tured in the presence of the synthetic MMP inhibitors
(Figure 1, B and D). As MT1-MMP–null mice display
profound defects in multiple organ systems that might
indirectly affect myocardial responses to noxious stim-
uli,39,41,42 the collagenolytic activity of MT1-MMP
heterozygous explants were examined. MT1-MMP/
mice are phenotypically indistinguishable from WT
mice,49,61 but heterozygous explants displayed an inter-
mediate level of hydroxyproline release that was signifi-
cantly decreased relative to WT controls (Figure 1D).
Although MT1-MMP can initiate the processing of the
MMP-2 and MMP-9 zymogens to their active forms,62,63
levels of processed MMP-2 and MMP-9 were unaffected
by decreasing the MT1-MMP gene dosage (Figure 1E).
MT1-MMP Is Engaged in Ischemic Myocardium
in Vivo and Regulates Acute Post-MI Survival
As MT1-MMP served as the key effector of myocardial
collagenolysis in ex vivo explants, expression of the
mRNA encoding this protease was monitored during
early (ie, 3 days) and late (28 days) post-MI cardiac
MT1-MMP and Myocardial Remodeling 1867
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detected by in situ hybridization of normal hearts (ie,
noninfarcted, control mice; data not shown), but a dra-
matic increase in MT1-MMP mRNA expression was
detected both within the zone of infarction as well as in
remote myocardial tissues at 3 days postinfarction
(Figure 2, A and B). Expression of MT1-MMP mRNA
was sustained in the infarct zone throughout the late
remodeling phase, with MT1-MMP expression ob-
served in the thinned left ventricular wall at 28 days
postinfarction (Figure 2, B and C), correlating with per-
sistent MT1-MMP–dependent (as well as other MT-
MMP family member–dependent) activity as assessed
by proteolytic processing of MMP-2.36
To assess the functional role of MT1-MMP expres-
sion on post-MI remodeling and cardiac function in
vivo, adult MT1-MMP/ mice were used in place of
the null animals because MT1-MMP/ mice display
early morbidity and mortality that preclude further
testing.39,42 Consistent with the normal phenotypic
appearance of MT1-MMP/ mice, no significant dif-
ferences in baseline cardiac function and relevantco-parameters including heart and body weight, hemo-
dynamics, echocardiographic parameters or electro-
cardiographic intervals were detected between he-
terozygous mice and littermate controls (Table 1).
Further, within 24 hour of coronary artery ligation, acute
mortality was comparable between the WT and MT1-
MMP/ mice (data not shown). Infarction was con-
firmed by wall-motion abnormality on echocardiogra-
phy, changes on electrocardiography, and distal
coronary vessel blanching following ligation (data not
shown). Subsequent long-term post-MI overall survival,
however, was increased over twofold at 4 weeks in
the MT1-MMP/ population (78%) relative to MT1-
MMP/ mice (36%; Figure 3A). At 4 weeks post-MI,
marked differences in the expression of MMP-2,
MMP-8, MMP-13, or MMP-9 were not detected bet-
ween MT1-MMP/ and MT1-MMP/ mice (Figure
3B). Furthermore, levels of latent and processed
MMP-2 or MMP-9 in MT1-MMP/ myocardial tissue
were comparable to those detected in WT tissue (Fig-
Figure 1. Ex vivo model assessing role of MT1-
MMP in collagen degradation using ischemic
myocardial explants. A: Sirius Red staining of
interstitial collagen (red) and denatured collagen
staining (green) in adult WT heart tissue at base-
line and following 5 days incubation in the ab-
sence or presence of BB-94. Scale bars: 20 m.
Quantification of collagen volume fraction (%)
and degraded collagen (arbitrary units, AU) as
shown (mean  SEM). *P  0.05. B: Collagen
degradation as monitored by the release of hy-
droxyproline-containing fragments from ex-
plants of adult WT mouse heart tissue after 3
days or 5 days incubation in the absence or
presence of the MMP inhibitors, BB-94 or
GM6001 (mean  SEM). C: RT-PCR analysis of
MMP-2, MMP-8, MMP-9, MMP-13, and MT1-
MMP expression in heart explants of WT tissue at
baseline and after a 5-day culture period. Results
are representative of three independent experi-
ments performed. D: Hydroxyproline solubiliza-
tion was determined after a 5-day culture period
of cardiac explants isolated from adult WT,
MMP-2/, MMP-8/, MMP-9/, MMP-13/,
MT1-MMP/, or MT1-MMP/ mice (mean 
SEM). E: Gelatin zymography of heart tissue ex-
plants from MT1-MMP/ or MT1-MMP/ ex-
plants at baseline versus after a 5-day culture
period. The pro- and processed forms of MMP-9
and MMP-2 are indicated.ure 3C). Death in both groups of mice was attributed
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arrhythmia, whereas ventricular rupture occurred only
rarely (data not shown).
Postinfarct Cardiac Structure/Function
Preservation in MT1-MMP/ Mice
Three days post-MI, MT1-MMP/, and MT1-MMP/
hearts displayed similar areas at risk as assessed by
histology and echocardiography, indicating that compa-
rable areas of injury arise following coronary ligation
(Figure 4A). However, progressive changes subse-
quently ensued that resulted in a significant reduction in
the final infarct size in the MT1-MMP/ mice at 28 days
(Figure 4B). In addition, MT1-MMP/ hearts exhibited a
small, but statistically significant, decrease in left ventric-
ular dilatation, as reflected by a higher ventricular wall
thinning ratio (ie, ratio of infarcted wall thickness to septal
thickness) (Figure 4B). Moreover, compensatory post-MI
myocardial hypertrophic responses were correspond-ingly blunted in the MT1-MMP/ mice as assessed by
decreases in myocyte cross-sectional area as well as LV
mass and LV diameter in noninfarcted regions of the
heart (Figure 4B).
Consistent with the improved structural status of the
post-infarct myocardium in MT1-MMP/ mice, cardiac
functional parameters (ie, fractional shortening and ejec-
tion fraction) were improved significantly in these mice 28
days postligation (Figure 4C). Furthermore, whereas
MT1-MMP/ mice displayed reduced cardiac function
as early as 3 days post-MI, MT1-MMP/ mice did not
display comparable decremental changes in function un-
til 7 to 14 days (Figure 4C, Supplemental Figures S1 and
S2 at http://ajp.amjpathol.org, and data not shown). Dia-
stolic parameters of isovolumic relaxation time and E/A
ratio showed a trend toward less dysfunction in the MT1-
MMP/ mice, but the degree of change was not statis-
tically significant (see Supplemental Figure S1 at http://
ajp.amjpathol.org). Covariable parameters, including
Figure 2. Expression kinetics and localization of
MT1-MMP in the post-MI myocardium. A: In situ
hybridization of cardiac cross sections 3 days
post-MI using MT1-MMP antisense (AS) or sense
(S) probes. Arrows indicate scattered foci of
MT1-MMP expression. Images obtained with the
sense probe were highlighted in darkfield micro-
graphs (right). B: Representative micrographs of
in situ hybridization for MT1-MMP expression in
cross sections of WT hearts using darkfield im-
ages (MT1-MMP antisense probe appears as
white/silver foci) at baseline and 3 or 28 days
post-MI in the infarct, border, and remote zones,
respectively. Scale bars: 100 m. C: Relative
quantification of MT1-MMP in the infarct zone
and border zone or remote viable myocardium in
WT heart tissue at baseline, 3, or 28 days postin-
farction (mean  SEM). *P  0.05.resting heart rates and systemic vascular resistance,
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nificant differences between the MT1-MMP/ and MT1-
MMP/ mice were detected (see Supplemental Figure
S2 at http://ajp.amjpathol.org). Taken together, these find-
ings demonstrate that MT1-MMP deficiency imparts a
protective effect on the adverse LV remodeling that fol-
lows myocardial infarction by reducing both the exten-
sion of infarct size and the degree of LV dilation.
MT1-MMP Gene Dose Regulates Functional
Remodeling of the Cardiac Stroma in a
Myocardium-Intrinsic Fashion
Following MI, MT1-MMP–dependent remodeling of the
cardiac ECM is potentially effected by resident car-
diomyoctyes and cardiac stromal cells (ie, fibroblasts
and endothelial cells) working in collaboration with in-
filtrating inflammatory leukocyte populations and other
bone marrow–derived cell populations.9 To begin
characterizing the tissue of origin of cells responsible
for MT1-MMP–dependent cardiac remodeling, inflam-
matory cell influx was assessed in MT1-MMP/ and
MT1-MMP/ hearts following coronary ligation. At 3
days post-MI, inflammatory cell influx into the necrotic
myocardium and border zone region consisted mainly
of polymorphonuclear leukocytes (CD45) and mono-
nuclear cells/macrophages (F4/80) (Figure 5A). Al-
though slightly lower numbers of neutrophils were ob-
served within the infarcted region of MT1-MMP/
Table 1. Baseline Comparison of MT1-MMP/ and
MT1-MMP/ Mice
MT1-MMP/ MT1-MMP/
Baseline
BW, g 25.7  0.4 26.2  1.1
HW/BW ratio, mg/g 6.52 0.10 6.43  0.13
Systolic blood pressure,
mm Hg
131  5 129  9
HR, beats/minute 529  72 520  36
Heart rate variability,
beats/minute
11.1  3.0 9.8  3.6
PR, ms 25.5  2.8 24.5  1.6
QRS, ms 10.3  0.9 9.6  0.7
QTc, ms 45.9  3.2 44.6  1.9
LV mass, mg 35.9  11.8 39.1  9.8
LV mass/BW, mg/g 3.60 0.09 3.62  0.93
LV ejection fraction, % 79 4 81  3
Fractional shortening, % 41  4 43  4
Left ventricular internal
diameter, mm
2.57  0.40 2.65  0.41
Interventricular septal
thickness, mm
0.60  0.10 0.63  0.10
Relative wall thickness,
mm/mm
0.42  0.03 0.43  0.13
E/A ratio 1.9  0.3 1.8  0.4
Cardiac output, L/minute 5.9  2.4 6.9  3.1
Cardiac index,
mL/minute/g
584  74 591  33
Comparisons were made using echocardiography, electrocardiogra-
phy, and noninvasive sphygmomanometry techniques on mice at 12
weeks of age.
BW, body weight; HR, heart rate; HW, heart weight; LV, left ventricular;
QTc, heart rate–correct QT interval.mice, these differences were not significant (Figure5A). By contrast, significantly reduced numbers of
macrophages (as well as total leukocyte numbers) lo-
calized to the infarcted region of MT1-MMP/ mice
(Figure 5A). Despite the decreased macrophage con-
tent of the MT1-MMP/ infarcted myocardium, levels
of circulating monocytes as well as neutrophils were
increased in MT1-MMP/ mice relative to MT1-
MMP/ mice at 3 days post-MI (0.62  0.28  103 vs.
0.27  0.19  103 cells/L and 1.21  0.07  103 vs.
0.39  0.04  103 cells/L, respectively).
Macrophage-derived MT1-MMP has been impli-
cated in pathologic interstitial ECM remodeling,64,65
raising the possibility that the enhanced post-MI sur-
vival observed in MT1-MMP/ mice arises as a result
of altered macrophage function. As such, congenic WT
Figure 3. Enhanced postinfarction survival in MT1-MMP/ mice. A: Sur-
vival of MT1-MMP/ and MT1-MMP/ mice after coronary artery ligation.
Lifespan was estimated by the Kaplan-Meier method. Percentages of surviv-
ing WT (MT1-MMP/; n  11) and MT1-MMP heterozygote (MT1-MMP/;
n  10) are shown at 0, 7, 14, 21, and 28 days post-MI. *P  0.05. B: RT-PCR
analysis of MMP-2, MMP-8, MMP-9, MMP-13, and MT1-MMP expression in
MT1-MMP/ and MT1-MMP/ infarcted tissue at 28 days post-MI. C:
Gelatin zymography of infarcted heart tissue isolated from MT1-MMP/ and
MT1-MMP/mice 28 days post-MI. The pro- and active forms of MMP-9 and
MMP-2 are indicated. Results are representative of three independent exper-
iments performed.
*P  0.05 compared to baseline within genotypes; P  0.05 compared to
WT heart at the respective time points.
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MMP/ mice (Figure 5B). Leukocyte blood counts
performed 12 weeks after transplantation in MT1-
MMP/ mice were similar to those in WT mice, as was
the degree of initial inflammatory cell infiltration during
the immediate post-MI period (data not shown). How-
ever, the post-MI LV functional status of MT1-MMP/
mice transplanted with MT1-MMP/ bone marrow
was similar, if not identical, to that observed in MT1-
MMP/ mice transplanted with MT1-MMP/ bone
marrow (Figure 5C). Hence, the preserved cardiac
function observed post-MI in MT1-MMP/ mice is
mediated by cells intrinsic to the myocardium itself,
with little or no effect of the MT1-MMP gene dose
expressed within bone marrow–derived cell popula-
tions.
Given a dominant role for myocardial-derived MT1-
MMP in regulating post-MI cardiac structure and func-
tion, the features of cells intrinsic to the myocardium
during post-MI tissue remodeling were next assessed. As
endothelial cells mobilize MT1-MMP during angiogene-
sis, a critical aspect of tissue remodeling,40 microvessel
density was assessed in the border zone adjacent to
the infarct zone at 3 and 28 days post-MI in MT1-
MMP/ and MT1-MMP/ hearts. As assessed by
platelet endothelial cell adhesion molecule 1 (PE-
CAM-1) staining,40 vessel numbers were not signifi-
cantly different between genotypes (Figure 5D). More-
over, significant differences in the number of apoptotic
myocytes and fibroblasts were not detected post-MI
between the two genotypes (Figure 5E).
Post-MI Collagen Catabolism Is Attenuated in
MT1-MMP–Deficient Mice, Resulting in
Preserved Interstitial Collagen Matrix
Given MT1-MMP’s role as a pericellular collagenase
and its regulation of collagen metabolism in the myo-
cardium ex vivo, collagen metabolism was examined in
WT and MT1-MMP/ hearts following coronary artery
ligation. At 3 days post-MI, type I collagen degradation
products were readily detected both within the infarct
zone and border region surrounding necrotic cardio-
myocytes in WT mice, whereas decreased levels of
type I collagen degradation were detected in the in-
farct and border zone (but not remote) regions of the
MT1-MMP/ mice (Figure 6A). To determine whether
the decrease in collagenolysis associated with MT1-
MMP heterozygosity altered steady-state collagen lev-
els in the postinfarct heart, the fibrillar collagen content
was determined within both the infarct border and re-
mote regions in MT1-MMP/ and MT1-MMP/
hearts. As assessed by Sirius Red staining under cir-
cularly polarized light, thicker interstitial collagen fibers
(constituting type I and/or type III collagen-containing fibrils)
were identified as the dominant fibrillar collagen in the
post-MImyocardium as compared to thinner collagen fibersFigure 4. Preservation of cardiac structure and function in MT1-MMP
heterozygous mice. A: Micrographs of H&E-stained cross sections of
whole hearts recovered from adult MT1-MMP/ and MT1-MMP/ mice
at baseline, 3, and 28 days post-MI. Scale bar  1 mm. B: Quantitative
assessment of left ventricular remodeling using established measures of
infarct size, septal wall thickness (wall thinning ratio), myocyte hypertro-
phy, LV internal diameter (at diastole and at systole), relative LV wall
thickness at systole, and LV mass at baseline, 14, or 28 days post-MI.
(mean  SEM). Structural assessment of the left ventricular internal di-
ameter and relative wall thickness were determined using two-dimen-
sional echocardiography on MT1-MMP/ and MT1-MMP/ mice at
baseline and 14 or 28 days post-MI. Myocyte hypertrophy (area) was
quantified using established measures in histological sections at baseline
and 28 days post-MI (mean  SEM). *P  0.05 compared to baseline
within genotypes; †P  0.05 compared to WT heart at the respective time
points. C: Measurement of ejection fractions and fractional shortening
using standard echocardiography are shown in MT1-MMP/ and MT1-
MMP/ mice at baseline and 14 versus 28 days post-MI (mean  SEM).
†at the 28-day time point (Figure 6B).53–56,66 Relative to WT
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higher content of the thicker collagen fibers in post-MI
tissue with an equal content of thinner collagen fibrils,
resulting in a net increase in the ratio of thick-to-thin
fibers (Figure 6B). Consistent with these findings, the
collagen content of the infarct zone as determined by
total hydroxyproline content was increased signifi-
cantly by 20% in MT1-MMP/ mice (Figure 6B).
Although MT1-MMP activity can potentially impact typeI collagen expression by modulating the local trans-
forming growth factor (TGF)-1 concentration,
67–70
type I collagen transcript levels were indistinguishable
in the infarct border and remote zones of MT1-MMP/
and MT1-MMP/ hearts as assessed by in situ hybrid-
ization (Figure 6C). Taken together, these results sug-
gest that myocardial MT1-MMP regulates post-MI ven-
tricular remodeling by effecting turnover of the type I
Figure 5. Myocardium-intrinsic role of MT1-MMP in regulating post-MI cardiac
function. A: Micrographs (top) of H&E sections of the infarct zone and the
peri-infarct, viablemyocardium from adultMT1-MMP/ andMT1-MMP/mice
at 3 days post-MI. Scale bar  100 m. Arrows indicate examples of infiltrating
leukocytes within the interstitial space. Neutrophil, macrophage, and leukocyte
infiltration in the infarct and remote LV regions was quantified (bottom) using
CD45- andF4/80-staining andmorphological analysis, respectively (mean SEM).
*P  0.05. B: PCR analysis of HPRT (minicassette marker designating disrupted
allele encodingMT1-MMP) andWTMT1-MMP locus in samples of bone marrow,
peripheral blood cells and splenic T-cells in mice 12 weeks after receiving bone
marrow transplantation showing complete engraftment of donormarrow.C:Mea-
surement of systolic cardiac function parameter ejection fraction and structural
cardiac assessment of the left ventricle internal diameter in Group A [WT to
heterozygous (HT) transplant, n 4] versus Group B (HT to HT transplant, n
4) mice at baseline, 14 days, and 28 days post-MI (mean  SEM). *P  0.05. D:
Representative micrograph of PECAM-1 (red) stained sections in the border zone
ofMT1-MMP/ andMT1-MMP/mice at 3 days post-MI. Number of microves-
sels per square millimeter were quantified (mean  SEM). *P  0.05. E: MT1-
MMP/ or MT1-MMP/ myocardium was stained for TUNEL 3 days post-MI.
Numbers of TUNEL-positive cells per square millimeter were tabulated (mean 
SEM).collagen ECM.
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myocardial tissue in the infarct zone, border zone, or remote viable myocardium of adult MT1-MMP/ and MT1-MMP/ mice following immunostaining
with an antibody specific for denatured type I collagen (brown). Tissue was isolated 3 days post-MI. Scale bar  10 m. Quantification of type I collagen
degradation activity at baseline, 3 days, or 28 days post-MI for MT1-MMP/ and MT1-MMP/ mice in the three myocardial zones (AU, arbitrary units;
mean  SEM). *P  0.05 compared to baseline within genotypes; †P  0.05 compared to WT heart at the respective time points. B: Sirius Red staining of
interstitial collagens using light microscopy and circularly polarized light (insets) in the infarct, border zone, and remote viable myocardium from adult
MT1-MMP/ and MT1-MMP/ mice 28 days post-MI. Scale bar  10 m. Quantitative assessment of collagen volume content using digital analysis of
Sirius Red–stained sections imaged with circularly polarized light; total collagen content in tissue by hydroxyproline analysis; and relative thick and thin
collagen fibril content using hue analysis of Sirius Red–stained sections in the MI zone and remote myocardium in MT1-MMP/ and MT1-MMP/ mice
at 28-day postinfarction (mean  SEM). *P  0.05 compared to baseline within genotypes; †P  0.05 compared to WT heart. C: Micrographs of in situ
hybridization in the infarct zone, border zone, and remote viable myocardium of adult MT1-MMP/ and MT1-MMP/ mice hearts using standard light
microscopy with darkfield imaging of the type I collagen mRNA antisense probe 3 days post-MI. Scale bar  10 m. Quantification of type I collagen probe
signal at baseline, 3 days, or 28 days post-MI for MT1-MMP/ and MT1-MMP/ mice in the three myocardial zones (mean  SEM). *P  0.05.
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MT1-MMP in Cardiac Fibroblasts
Current evidence suggests that cardiac fibroblasts and
myofibroblasts play a central role in remodeling of the
cardiac interstitial matrix.71–73 Hence, cardiac fibroblasts
were isolated from MT1-MMP/, MT1-MMP/, and
MT1-MMP/ myocardial tissues and their relative type I
collagenolytic activity assessed in vitro. As determined by
RNA microarray analysis, these cells express vimentin
and -smooth muscle actin at comparable levels, with no
desmin expression detected (data not shown). First, a
suspension of cardiac fibroblasts was allowed to adhere
in the center of a three-dimensional sheet of type I colla-
gen fibrils. After culturing the fibroblasts in the presence
of platelet-derived growth factor BB (PDGF-BB) for 5
days, the cells were lysed and the residual collagen film
stained with Coomassie Blue. As shown in Figure 7A,
MT1-MMP/ fibroblasts degraded qualitatively less
subjacent type I collagen than WT fibroblasts, whereas
MT1-MMP/ fibroblasts did not display any detectable
type I collagenolytic activity. Next, to quantitatively as-
sess MT1-MMP–dependent type I collagenolysis, PDGF-
BB–stimulated fibroblasts were cultured atop a bed of
Alexa Fluor-594–labeled type I collagen and
collagen degradation monitored by confocal laser mi-
croscopy. WT cells degraded the subjacent type I colla-
gen film (visualized as dark “holes”) of variable two-di-
mensional areas via a process that was abolished in
MT1-MMP/ fibroblasts (Figure 7, B and C). Although
MT1-MMP/ cells retained significant collagenolytic ac-
tivity relative to MT1-MMP–null cells, the heterozygous
cardiac fibroblasts generated significantly fewer degra-
dative zones with smaller average two-dimensional area,
reflecting less efficient type I collagenolysis (Figure 7, B
and C). Thus, in a fashion consistent with the enhanced
preservation of the type I collagen network observed
post-MI in MT1-MMP/ mice, these results define an
essential role for MT1-MMP in regulating cardiac fibro-
blast–mediated type I collagenolysis.
Discussion
Following MI, the collagenous fabric of the myocardium
undergoes extensive remodeling, both acutely and
chronically, as wound healing programs are initiated to
remove damaged tissues and viable portions of the in-
jured heart mount adaptive hypertrophic processes in an
effort to maintain mechanical function.6,7,74,75 As a con-
sequence of these matrix remodeling events, the altera-
tions that occur in collagen synthesis, degradation, and
organization in the post-MI state ultimately precipitate
cardiac dysfunction.2,5–7 Despite the wealth of evidence
that collagenolytic MMPs are expressed at increased
levels in the diseasedmyocardium,15,76–78 and that cardiac
function can worsen or improve in tandem with respective
increases or decreases in MMP activity,13,23–26,28,68,79,80
the identity of the collagenolytic MMP(s) responsible for
these effects has remained the subject of speculation.
From a developmental perspective, secreted collage-Figure 7. MT1-MMP–dependent collagen degradation in isolated cardiac
fibroblasts. A: Collagenolytic activity of PDGF-BB–stimulated (50 ng/mL)
MT1-MMP/, MT1-MMP/, or MT1-MMP–null cardiac fibroblasts seeded
atop type I collagen gels. Zones of collagenolytic activity are visualized after
Coomassie Blue staining following a 5 days culture period. Hydroxyproline
release was quantified after a 5-day culture period (n 3; mean SEM) *P
0.05. B: Isolated cardiac fibroblasts from WT, MT1-MMP heterozygote, and
MT1-MMP–deficient cardiac fibroblasts were cultured atop TRITC-labeled
type I collagen gel films (100 g/cm2) for 7 days in the presence of PDGF-BB
(50 ng/mL) and visualized with Alexa Fluor-488 phalloidin with fluorescent
images captured by laser scanning confocal microscopy. Scale bar  10 m.
C: Quantification of the number and size of degradative zones per high-
powered field formed in vitro by cardiac fibroblasts isolated from MT1-
MMP/, MT1-MMP/, or MT1-MMP/ mice as described in (B). The
number and size of degradative zones was determined in five randomly
selected fields.
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regulating type I collagen turnover in the in vivo set-
ting.16,35,37 More recently, this proposition has under-
gone revision as studies of MMP-8/, MMP-13/,
MMP-2/, or MMP-9/ mice have demonstrated that
each of the respective knockout animals are viable and
fertile, with only subtle defects in ECM remodeling.35,44–46,81
By contrast, mounting evidence indicates that MT1-MMP
plays a central role in type I collagen turnover—a finding
consistent with the fact that the null nice display multiple
defects in tissue remodeling in vivo and die within weeks
of birth.39,41,42 Interestingly, however, the structural/func-
tional impact of MT1-MMP targeting on cardiac remodel-
ing in the post-MI heart has remained largely unstudied.
To probe for collagenolytic systems activated within
infarcted tissues, we first focused our efforts on culturing
cardiac explants recovered from WT mice under no-flow
conditions designed to recapitulate an ischemic environ-
ment.47 In response to this in vitro stress, explants up-
regulated expression of MMP-9, MMP-13, and MT1-
MMP—a pattern similar to that observed in vivo.18,76–78,82,83
Although MMP-8 mRNA was not detected under these
conditions, this result is consistent with the fact that in
vivo, MMP-8 expression is confined largely to infiltrating
neutrophil populations.78 Further confirming the rele-
vance of the model, and coincident with the expression of
collagenolytic proteases, type I collagen degradation
products accumulated within the explanted tissues in a
process that could be blocked by MMP inhibitors. When
this experimental model was extended to myocardial ex-
plants of MMP-targeted mice, only MT1-MMP deficiency
ablated the collagenolytic activity of the cardiac explants
to a degree similar to that observed with the pan-specific,
synthetic MMP inhibitors. Our inability to implicate se-
creted MMPs in the collagenolytic phenotype activated in
tissue explants is consistent with findings demonstrating
that MMP-8, MMP-13, MMP-2, or MMP-9 display only
limited collagen-degradative activity in the antiprotease-
rich, plasma- or serum- replete environments that char-
acterize the in vivo setting.35,36,84 These observations do
not allow for the conclusion that secreted collagenases
are uniformly inoperative in all in vivo scenarios. Rather,
these enzymes are only able to circumvent the antipro-
tease screen under conditions in which either the local
concentration of active proteases exceeds that of pro-
tease inhibitors or antiprotease function is dissipated as a
consequence of oxidative or proteolytic inactivation.35,84
By contrast, MT1-MMP, which is expressed at the cell
surface in a membrane-tethered, active form, retains
full collagenolytic activity at the cell–matrix interface
even in the presence of high concentrations of antipro-
teases.35,36,38
Given the morbid status ofMT1-MMP–null mice, in vivo
studies designed to interrogate the role of MT1-MMP in
the post-MI state were limited to the use of mice heterozy-
gous for an MT1-MMP–null allele. Although MT1-
MMP/ mice are phenotypically normal, recent studies
have demonstrated that these animals enjoy a protected
status when challenged by pathological injuries ranging
from intimal hyperplasia to high-fat diet–induced obe-
sity.49,61 With regard to cardiovascular function, we nowfind that MT1-MMP/ mice also display a significant
post-MI survival benefit while better preserving myocar-
dial structure and function. Reductions in post-MI LV
dilation and dysfunction along with increased cardiac
performance in MT1-MMP/ mice each correlated
closely with increases in local type I collagen content as
a consequence of decreased interstitial collagenolysis.
These findings do, however, contrast with those reported
recently by Spinale and colleagues68–70 wherein MT1-
MMP has been proposed to regulate post-MI fibrotic re-
sponses within the myocardium by controlling TGF-1
signaling. In these authors most recent work, MT1-
MMP/ mice were likewise noted to display a post-MI
protected status, but this correlated with a decrease—
rather than the increase observed in our report—in type I
collagen content within the infarct zone as assessed by
Sirius Red staining.70 As opposed to the studies pre-
sented herein, although collagen volume fractions were
determined by morphometry, neither local type I collagen
degradation nor total collagen hydroxyproline content
was quantified, and the bulk of the effect observed re-
garding the decreased collagen content ofMT1-MMP/
infarct zones appears to be attributed to the lower colla-
gen content of the heterozygote hearts before infarc-
tion—an effect that we were unable to verify.70 Further-
more, although Zavadzkas et al70 postulated that the
decreased type I collagen content observed in the infarct
zone of MT1-MMP/ mice arose as a consequence of a
local decrease in MT1-MMP–dependent TGF- activa-
tion, a number of caveats apply. First, the assumed de-
crease in TGF- activation is based on the ability of
myocardial extracts to hydrolyze a synthetic peptide
whose sequence includes a previously identified MT1-
MMP cleavage site in the TGF- latency-binding protein,
LTBP-1.70 The in situ cleavage of LTBP-1 in MT1-
MMP/ or MT1-MMP/ mice was not actually mon-
itored in their studies.70 Second, this issue notwith-
standing, although others have demonstrated
previously that MT1-MMP can release latent TGF-1
from ECM-bound sites as a consequence of hydrolyz-
ing TGF- latent-binding proteins,85 the ability of MT1-
MMP to participate in the activation of the solubilized, but
still latent, TGF-1 remains unclear. Third, though data
are presented in support of decreased TGF- signaling in
the postinfarct MT1-MMP/ myocardium (as assessed
by Smad3 phosphorylation), total Smad3 levels were in-
explicably reduced in the cardiac tissues harvested from
the heterozygote mice.70 Because decreased levels of
Smad3 are frequently observed as a consequence of
increased TGF- signaling,86 the almost complete ab-
sence of Smad3 in post-MI tissues harvested from MT1-
MMP/ mice may indicate that other mechanisms are
operative here. Finally, type I collagen mRNA levels
(which one would predict to be decreased as a conse-
quence of diminished TGF- signaling11) were not mon-
itored.70 As noted, we were unable to detect changes in
local type I collagen expression post-MI in MT1-MMP/
versusMT1-MMP/mice, suggesting that the observed
increased collagen in the infarct zone of MT1-MMP/
mice 28 days post-MI likely results from attenuated pro-
teolysis as a consequence of 50% reduction in the
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MT1-MMP/ andMT1-MMP/ gene expression in car-
diac fibroblasts cultured in three-dimensional type I col-
lagen hydrogels have failed to detect differences in TGF-
–related signaling pathways or the expression of
downstream TGF- targets (G. Koenig, F.S., and S.J.W.,
unpublished data). Conclusions similar to our own were
also reached in a recent study by Kandalam et al27
wherein postinfarct remodeling of fibrillar collagen was
monitored in mice harboring an inactivating mutation in
TIMP2, the major inhibitor of MT1-MMP in vivo. In these
studies, TIMP2 deficiency resulted in an increase in MT1-
MMP activity within the infarct zone, whereas local fibrillar
collagen content was decreased.27 Even so, given the
range of potential MT1-MMP targets,87 it will likely prove
difficult, if not impossible, to identify a single target for the
protease in the infarcted myocardium. Based on the ob-
servation that transgenic mice harboring knockin type I
collagen mutations (r/r collagen) that render the molecule
resistant to collagenolytic attack are not protected from
pathological post-MI interstitial remodeling, Lindsey et
al88 concluded that pathological activity attributed to car-
diac MMPs arises as a function of a substrate repertoire
that lies outside of type I collagen per se. However, this
conclusion can only be cautiously embraced as we have
found that r/r collagen is readily degraded by mouse
fibroblasts in vitro as well as in vivo (F.S. and S.J.W.,
unpublished data). Nevertheless, as type I collagen plays
an unchallenged role in defining cardiac structure and
function,1,2,4–7 it seems likely that the collagenous matrix
remains a dominant MT1-MMP–targeted substrate.
Independent of the identification of the critical MT1-
MMP substrates in the damaged myocardium, caution
must also be exercised in attributing all changes in ECM
remodeling to the ability of MT1-MMP to function as a
direct-acting, proteolytic effector. In this regard, MT1-
MMP–dependent effects are frequently attributed to its
ability to directly or indirectly catalyze the processing of
MMP-2, MMP-13, or MMP-9 zymogens to their active
forms.62,63,89,90 Previous studies have demonstrated that
MMP-2/ as well asMMP-9/mice are also protected—
to varying degrees and via distinct mechanisms—from
postinfarct cardiac dysfunction.30–32 Recently, it was re-
ported that an MMP-2–null status afforded transgenic
mice with a survival advantage following infarct induction
by modulating macrophage accumulation and the clear-
ance of necrotic debris from damaged tissues.32 Though
long-term improvements in cardiac function were not de-
tected in this study, other reports suggest that left ven-
tricular dysfunction is blunted in MMP-2/ mice, but
without changes in collagen content.31 MMP-9/ mice
may also show improvements in cardiac function follow-
ing coronary artery ligation, but in these animals, type I
collagen content decreased in the knockout cohort,
whereas other investigators have documented increases
in post-MI angiogenic responses.30,91 Clearly, these
studies indicate that secreted MMPs also impact the
post-MI remodeling program, but that the underlying
mechanisms are complex and unlikely to reflect direct
changes in type I collagen degradation or remodeling.
Rather, these protective effects are more likely linked tothe ability of MMP-2 and MMP-9 to modulate growth
factor release, the release of bioactive ECM fragments or
the local activation/inactivation of chemokines and
growth factors.16,92 Nevertheless, despite potential roles
for MMP-2 and MMP-9 in postinfarct remodeling, we
noted that cardiac tissues recovered from MT1-MMP/
mice express levels of processed MMP-2 and MMP-9
similar to those observed in WT littermates. As such, we
posit that the protective effects exerted by the MT1-MMP
heterozygous state manifest themselves as a direct con-
sequence of MT1-MMP activity alone.
The multiplicity of cell types capable of generating
MT1-MMP in vivo complicates efforts to assign a particu-
lar cell type as the primary effector of collagenolytic ac-
tivity in the postinfarct myocardium. Cardiomyocytes, en-
dothelial cells, and cardiac fibroblasts are all able to
generate MT1-MMP.40,78,93,94 Furthermore, inflammatory
cell populations, including monocytes and macrophages
as well as bone marrow–derived cells (eg, bone marrow
stromal/stem cells, fibroblasts, etc) that are recruited to
sites of cardiac damage likely express MT1-MMP as
well.64,65 In our studies, however, the replacement of the
heterozygous bone marrow with transplanted WT marrow
did not alter the cardiac-protective effects exerted by the
MT1-MMP/ status. Within the myocardium itself, car-
diac fibroblasts seem the most likely cell type responsible
for type I collagenolytic activity as these cells are the
dominant effectors of type I collagen synthesis, deposi-
tion, and remodeling.71,72 Indeed, our studies of isolated
cardiac fibroblasts demonstrated an absolute require-
ment for MT1-MMP in type I collagenolytic activity, and
confirmed the predicted blunting of the collagen-degra-
dative potential ofMT1-MMP/ cells. Although endothe-
lial cell–derived MT1-MMP plays a critical role in angio-
genesis,40,42,93 the vascularization of the infarcted
myocardium was unaffected in MT1-MMP/ mice rela-
tive to the control population. Likewise, cardiomyocytes
have also been reported to express MT1-MMP,78 but its
function in these cells remains to be established. In this
regard, it is important to stress that cardiomyocytes are
ensheathed by a basement membrane that would limit
MT1-MMP access to the surrounding interstitial matrix.2
Though transgenic mice that specifically overexpress
MT1-MMP in cardiomyocytes develop a number of car-
diac abnormalities and display aberrant post-MI remod-
eling,68–70 the requirement for endogenous cardiomyo-
cyte-derived MT1-MMP in post-MI remodeling remains to
be determined. In preliminary studies, we have gener-
ated transgenic mice wherein MT1-MMP expression in
cardiomyocytes has been deleted specifically, and anal-
yses of these mice are currently underway.
A key role for MT1-MMP in precipitating acute myocar-
dial damage as well as pathological left ventricular re-
modeling in the post-MI heart, coupled with the protective
effect exerted by the MT1-MMP heterozygous state,
raises the question of the utility of targeting the protease
for therapeutic intervention. Indeed, the continued ex-
pression of MT1-MMP throughout the entire 28-day
post-MI period monitored in our study supports a model
wherein continued type I collagen remodeling exacer-
bates left ventricular dysfunction. This conclusion is con-
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AJP May 2012, Vol. 180, No. 5sistent with prior studies using pan-specific MMP inhibi-
tors to reduce post-MI left ventricular remodeling and
improve cardiac function.21–24 However, despite comple-
mentary reports describing increased levels of MT1-MMP
following MI, these results contrast with the lack of benefit
of an MMP inhibitor given post-MI in human trials.95 Nev-
ertheless, interpretation of these results are complicated
by the fact that the dosing of MMP inhibitors used in these
studies appear to fall below those required to inhibit
MT1-MMP activity.24,96 Furthermore, as the mammalian
MMP family contains over 20 members whose wide-rang-
ing activities can both promote and inhibit myriad cell
functions,16,97 the use of pan-specific MMP inhibitors fur-
ther obfuscates attempts to gauge in vivo impact. Given
these caveats, many investigators in the field have con-
cluded that targeting specific MMPs, such as MT1-MMP,
in the in vivo setting may not be possible. Interestingly,
this hurdle may have been negotiated with the more
recent generation of humanized monoclonal antibodies
that specifically inhibit MT1-MMP catalytic activity in vitro
as well as in vivo.98 The availability of this new class of
MT1-MMP–specific inhibitors could provide investigators
with new tools to gauge the clinical utility of targeted
MT1-MMP inhibition in conditions associated with mal-
adaptive myocardial remodeling.
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